Elicio Therapeutics Inc. has announced updated immunogenicity results from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine for patients with KRAS-mutated pancreatic ductal adenocarcinoma. According to the company, ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89 out of 90), with robust immune responses observed across all seven mKRAS antigens. More than 80% of patients responded to each individual KRAS mutation, and 88% generated responses to their own tumor-specific mutation. Cytotoxic mKRAS-specific T cell responses were induced in 86.8% of patients (66 out of 76), with both CD8+ and CD4+ T cells detected in 75% of cases. The company remains blinded to the clinical efficacy outcomes of the trial. These data will be presented at the Society for Immunotherapy of Cancer $(SITC)$ 2025 Annual Meeting, scheduled for November 7-8, 2025, in National Harbor, MD. Additionally, preclinical data on ELI-004, an intra-tumoral immunotherapy, will also be presented at the meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570882-en) on November 07, 2025, and is solely responsible for the information contained therein.
Comments